Home > Boards > US OTC > Medical - Drugs > Telo Genomics Corp. (TDSGF)

3D Signatures appoints Louis CEO

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Bassman101 Member Profile
Followed By 2
Posts 205
Boards Moderated 0
Alias Born 02/05/10
160x600 placeholder
Bassman101   Wednesday, 09/26/18 02:36:59 PM
Re: None
Post # of 68 
3D Signatures appoints Louis CEO

3D Signatures Inc (C:DXD) ()OTC:TDSGF)
Shares Issued 46,445,199
Last Close 5/30/2018 $0.155
Tuesday September 25 2018 - News Release

Mr. Hugh Rogers reports


3D Signatures Inc. has appointed Dr. Sherif Louis, PhD, as the company's chief executive officer.

Dr. Louis is an accomplished scientist and experienced leader in the biotechnology industry. Dr. Louis was an early key contributor to the development of the company's 3-D telomere technology and TeloView software platform dating back almost 15 years. He has held various leadership and executive positions with Canadian non-profit orgaizations focused on advising and coaching for-profit biotech enterprises engaged in technology commercialization. Dr. Louis has also served on the board of directors of the Biotechnology Association of Manitoba. Dr. Louis formaly joined 3D Signatures in September, 2015, and most recently held the position of director of clinical operations.

"I am a true believer in the power of the TeloView software platform. I know the science intimately and I look forward to refocusing the company on large commercial opportunities in collaboration with strategic partners," said Dr. Louis.

"Dr. Louis is dedicated to delivering shareholder value through prudent allocation of company resources. 3DS will focus on opportunities that provide leverage through academic, clinical and industry partnersnips. We are confident that Dr. Louis is the right person to lead operations during this critical transition," said Hugh Rogers, interim chair.

About 3D Signatures Inc.

3D Signatures is a personalized medicine company with a proprietary software platform, TeloView, that is designed to predict the course of certain diseases and to tailor treatment options for the individual patient. The technology is based on the 3-D analysis of telomeres, the protective caps at the ends of chromosomes.

We seek Safe Harbor.

© 2018 Canjex Publishing Ltd.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences